Farnesoid X receptor (FXR), a nuclear receptor for maintaining bile acid homeostasis, has been recognized as a tumor suppressor in enterohepatic tissues. However, its expression and functional role in non-small cell lung cancer (NSCLC) remain unclear. We report that FXR is significantly increased in NSCLC and that it predicts poor clinical outcomes in NSCLC patients. FXR knockdown in NSCLC cells inhibited in vitro cell proliferation, blocked xenograft growth in nude mice, and delayed the G1/S transition of the cell cycle, whereas ectopic overexpression of FXR promoted NSCLC cell proliferation. Mechanistic analysis demonstrated that FXR could directly bind to an inverted repeat-0 sequence in the CCND1 promoter and activate its transcription. Cyclin D1 overexpression rescued NSCLC cells from the delayed G1/S transition and the impaired cell proliferation induced by FXR knockdown. Importantly, a positive correlation between the expression of FXR and cyclin D1 was confirmed in NSCLC samples, and patients with high expression of both FXR and cyclin D1 had the worst prognosis. In summary, our results suggest that FXR has oncogenic potential in NSCLC development, providing mechanistic insights that could be exploited for both prognostic and therapeutic purposes.
Scientific RepoRts | 7: 591 | DOI:10.1038/s41598-017-00698- 4 We previously reported that FXR was increased in idiopathic pulmonary fibrosis (IPF) lungs 16 . Beyond that, knockdown of FXR restrained BA-induced epithelial-mesenchymal transition and lung fibroblast activation, indicating a detrimental role of FXR in IPF pathogenesis. However, the expression and potential biological function of FXR in NSCLC have never been investigated yet. Here, we firstly showed that FXR was upregulated in NSCLC tissues, and its expression levels were positively correlated with poor clinical outcomes. We identified an oncogenic role of FXR in NSCLC development by uncovering a mechanistic link to cyclin D1. Furthermore, FXR-cyclin D1 signaling was found to predict a poor prognosis for NSCLC patients. This finding may permit the stratification of NSCLC in a novel way and may subsequently provide an intervention option.
Results
FXR is upregulated in NSCLC and predicts poor patient outcomes. We first assessed the FXR expression level by immunohistochemical (IHC) staining in 160 pairs of NSCLC and matched normal lung tissues. Intense nuclear FXR staining was observed in tumor cells but was rare in normal cells (Fig. 1A) . We found that FXR protein was significantly upregulated in carcinous, compared to pericarcinous, lung tissues (Fig. 1B) .
For further analysis, the NSCLC specimens were separated into two groups, defined as "FXR high" (scores of 6-12) and "FXR low" (0-4). Consistent with the previous observations, the proportion of "FXR high" specimens in NSCLC was significantly higher than that in matched normal lung tissues (61.2% vs. 0.6%, p < 0.001) ( Table 1 ). Statistical data showed that high FXR expression was positively associated with a more advanced pathological stage (p = 0.012) and T status (p = 0.025), as well as a larger tumor size (p = 0.03) ( Table 2 ), indicating the possible involvement of FXR in tumor growth and NSCLC progression.
The prognostic implication of FXR in NSCLC was subsequently analyzed. Kaplan-Meier survival curves showed that the overall survival (OS) was significantly worse in "FXR high" NSCLC patients than in those with low expression (p = 0.0032) (Fig. 1C ). Multivariate Cox regression analysis revealed that an "FXR high" pattern [hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.108-2.637; p = 0.015], as well as advanced stage (HR 1.773, 95% CI 1.171-2.685; p = 0.007), were independent predictors for poor OS in NSCLC (Table 3 ).
FXR promotes the proliferation of NSCLC cells, and knockdown inhibits tumor growth in vivo.
The FXR expression level in five NSCLC cells was evaluated by western blot and quantitative real-time PCR (RT-PCR). H1975 and H1299 had higher FXR protein and mRNA expression compared with H1650, H460 or HCC4006 cells ( Fig. 1D and E) . HCC4006 had the lowest FXR expression.
As the FXR expression level was correlated with poor clinical outcomes, we hypothesized that FXR might act as an oncogene in NSCLC. We used the downstream target, SHP, as an indicator of alterations in FXR activity with treatment 9 . The FXR antagonist Z-guggulsterone inhibited the proliferation of higher-FXR-expressing cell lines, H1975 and H1299, in a dose-dependent manner ( Fig. 2A and B ). FXR knockdown resulted in decreased proliferation of H1975 and H1299 cells ( Fig. 2C and D) . By contrast, enforced FXR in endogenous lowest-FXR-expressing cells HCC4006 significantly accelerated cell proliferation compared to a mock group, which was reversed by Z-guggulsterone ( Fig. 2E ). Ki-67 is a universal biomarker for proliferating cells 17 . Our immunofluorescence data showed that FXR silencing in H1975 compromised the intensity and proportion of Ki-67-positive cells, while ectopic FXR expression in HCC4006 had the opposite effects ( Fig. 2F and G).
Next, we evaluated the effect of FXR knockdown on NSCLC xenograft growth in vivo. H1975 cells that were transfected with FXR-or NC-shRNA were subcutaneously injected into nude mice. Figure 3A reveals significantly slower tumor growth according to the volumes in FXR knockdown groups compared to the control group. However, no marked difference in body weight was observed ( Fig. 3B ). After 32 days, tumors were isolated. We found that tumors derived from FXRshRNA-transfected H1975 cells had a significantly smaller tumor size and tumor weight compared to those from control cells ( Fig. 3C and D). These data indicated that FXR had proliferation-promoting properties in NSCLC.
Suppression of FXR causes G0/G1 cell cycle arrest and cyclin D1 reduction, independent of SHP in NSCLC.
Cell cycle arrest and apoptosis are considered two primary approaches in proliferation inhibition. We examined the effects of FXR on cell cycle and apoptosis in NSCLC cells. Both Z-guggulsterone and FXRsiRNAs increased the proportion of H1975 cells in the G0/G1 phase, and decreased the proportion in the S and G2/M phases ( Fig. 4A and B ). Similar trends were found in H1299 cells that underwent the same treatment ( Supplementary Fig. S1A and B) , indicating a critical role for FXR in the G1/S transition. However, no apparent change in apoptosis was observed in H1975 and H1299 cells upon either Z-guggulsterone or FXRsiRNAs treatment ( Supplementary Fig. S1G and H).
Certain regulators acting in the cell cycle G1/S transition were subsequently evaluated by western blot analysis 18 . As shown, the cyclin D1, CDK2, CDK4, CDK6, and phosphorylated Rb (p-Rb) protein levels were remarkably reduced in H1975 cell that were treated with Z-guggulsterone, while only cyclin D1 and p-Rb proteins were down-regulated by FXRsiRNAs ( Fig. 4C and D) . Similar changes were also found in H1299 cells ( Supplementary  Fig. S1C and D). In contrast, ectopic FXR expression in HCC4006 increased the cyclin D1 and p-Rb protein levels (Fig. 4E ). As a result, the influences of Z-guggulsterone on CDK2, CDK4, and CDK6 expression could be considered nonspecific 19 . Quantitative RT-PCR analysis demonstrated consistent results that both Z-guggulsterone and FXRsiRNAs reduced the cyclin D1 mRNA level in H1975 ( Fig. 4F and G) and H1299 cells ( Supplementary  Fig. S1E and F), whereas overexpression of FXR increased the cyclin D1 abundance in HCC4006 ( Fig. 4H ). Since cyclin D1 is required for Rb phosphorylation by CDK4/6 in cell cycle initiation 20 , we speculated that FXR might function as a positive regulator of cyclin D1 transcription and G1/S transition.
Furthermore, we addressed whether the effects of FXR in NSCLC depend on its downstream effector, SHP 9 . There was no detectable change in either in vitro proliferation or cyclin D1 and p-Rb expression in H1975 and H1299 cells that were transfected with SHPsiRNAs ( Fig. 4I -L). These findings imply that FXR induces cell proliferation and cyclin D1 expression through a mechanism that is independent of SHP in NSCLC.
FXR is recruited to the cyclin D1 promoter and promotes its transcription. FXR is a transcription
factor that controls target gene transcription through binding to an FXR-responsive element (FXRE) 21 . Gene sequence analysis revealed that the −2000/+209 region of the human CCND1 promoter contains a putative inverted repeat-0 FXRE sequence (GGGTAATTACCCC) at nucleotide −1539 from the transcription initiation site. To confirm the hypothesis that FXR might transactivate CCND1, a chromatin immunoprecipitation (ChIP) assay was performed. Its results showed that clear bands could be amplified from DNA samples immunoprecipitated by anti-FXR antibody in H1975 and H1299 cells, while no band was amplified in the negative controls (NC, isotype IgG) ( Fig. 5A -C), indicating that FXR can directly bind to the putative motif in the CCND1 promoter. We performed a luciferase reporter assay using luciferase reporter plasmids harboring the CCND1 promoter region with or without a wild-type FXRE sequence ( Fig. 5D ). To achieve more effective knockdown of FXR expression, only FXRsiRNA-2 was used. We observed that wild-type CCND1 promoter activity was significantly higher than that of the FXRE-deleted CCND1 promoter in H1975 cells ( Fig. 5E ). FXR knockdown in H1975 significantly reduced wild-type CCND1 promoter activity without reducing FXRE-deleted CCND1 promoter activity. Conversely, ectopic overexression of FXR in HCC4006 increased the wild-type CCND1 promoter activity by approximately 100% compared to the mock group, whereas deletion of the FXRE motif repressed this elevation ( Fig. 5F ). Z-guggulsterone retained the activity of the wild-type CCND1 promoter, rather than the FXRE-deleted ones, in FXR-overexpressed HCC4006 cells. These findings corroborated the contribution of FXR in directly activating cyclin D1 transcription in NSCLC. 
Overexpression of cyclin D1 rescues NSCLC cells from the antiproliferative effects induced by FXR suppression.
To examine the functional relevance of FXR and its target cyclin D1, rescue experiments were conducted. 3Flag-tagged cyclin D1 was forcefully expressed into H1975 and H1299 cells treated with either Z-guggulsterone or FXRsiRNAs, respectively; the effects on cell cycle distribution and in vitro proliferation were determined. Western blot analysis showed that cyclin D1 and p-Rb, both substantially reduced in Z-guggulsterone or FXRsiRNAs treated H1975 ( Fig. 6A and B ) and H1299 cells ( Supplementary Fig. S2A and B) , respectively, were increased in cells ectopically expressing cyclin D1. As depicted, overexpression of cyclin D1 partially reversed the delayed G1/S transition and the impaired in vitro proliferation induced by Z-guggulsterone in H1975 cells ( Fig. 6C and E). Similar changes were also found in H1299 upon the same treatment ( Supplementary Fig. S2C and E). Moreover, FXRsiRNAs-induced G0/G1 arrest and cell proliferation inhibition in H1975 and H1299 cells were almost completely abrogated in cells transfected with cyclin D1-3Flag, compared to vector control ( Fig. 6D ,F, and Supplementary Fig. S2D, F) . These results clearly demonstrated that upregulation of cyclin D1 expression was responsible for the proliferation-promoting function of FXR in NSCLC.
Correlation analysis of FXR and cyclin D1 expression in NSCLC specimens.
To further confirm the association between FXR and cyclin D1 in NSCLC, we assessed cyclin D1 expression by IHC in the same cohort of specimens. We detected significantly higher cyclin D1 levels in NSCLC compared to corresponding pericarcinous lung tissues ( Supplementary Fig. S3A ). Kaplan-Meier analysis revealed a significantly shorter OS in "cyclin D1 high" (scores 6-12) NSCLC patients than in "cyclin D1 low" (0-4) patients (p = 0.0113) ( Supplementary  Fig. S3B ), which was consistent with previous reports 22, 23 . Additionally, cyclin D1 protein was increased in "FXR high" tumors ( Fig. 7A and B) , and chi-square analysis demonstrated a positive correlation between FXR and cyclin D1 expression in NSCLC specimens (p < 0.001) ( Table 4) . Notably, a combinatorial expression pattern of "FXR high" and "cyclin D1 high" predicted the worst OS in NSCLC patients (p = 0.0077) ( Fig. 7C ).
Discussion
In this study, we identified FXR as a novel proto-oncogene that is markedly upregulated in NSCLC. Our data indicated that FXR contributes to tumor growth via directly transactivating CCND1 and then promoting cell cycle progression. Furthermore, the expression of FXR and cyclin D1 was found to be positively correlated in NSCLC samples and could cooperatively contribute to patient sub-stratification. To the best of our knowledge, this study is the first to comprehensively analyze the expression of FXR in NSCLC, as well as assess the functional role in carcinogenesis. FXR, an essential regulatory nuclear receptor for maintaining BA homeostasis, is deregulated in many malignancies 8 . It is well established that FXR deficiency leads to spontaneous liver tumors and increased colon cell proliferation in mice as well as increased small intestine adenocarcinoma formation in APC min mice, supporting a tumor-suppressive role of FXR in these cancer types 10, 12 . However, Guan et al. reported that FXR is overexpressed in esophageal adenocarcinomas, and that knockdown of FXR causes tumor cell growth inhibition both in vitro and in vivo 14 . Research on breast cancer has demonstrated that activation of FXR promotes cell proliferation within ER-positive cancer cells, indicating that this receptor likely has an oncogenic function 15 . In the present study, we provide compelling clinical evidence that in NSCLC, FXR is significantly increased and independently predicts poor outcomes. Additionally, FXR promoted NSCLC cell proliferation and tumorigenicity in both cultured cells and animal models, indicating that FXR could act as an oncogene in NSCLC development. These findings further highlight a dual role of FXR as either a tumor-suppressor or an oncogenic protein, suggesting the A and B) , or were transfected with NC-or FXR-siRNA sequences (C and D). HCC4006 stable cell lines were treated with Z-guggulsterone (40 μM) (E). The FXR and SHP protein expression levels in each cell line were determined by western blot two days later (upper graph). Cell proliferation was determined after the indicated treatment by using SRB assay at different time points (lower curve). Representative images of immunofluorescent staining of Ki-67 in H1975 cells transfected with NC-or FXR-siRNA sequences (F), and HCC4006 stable cell lines treated with Z-guggulsterone (40 μM) (G) at × 60 magnification. The nuclei were stained with DAPI. All experiments were repeated at least three times. *p < 0.05, compared with the control, NC, or mock group, respectively; † p < 0.05, compared with the FXR-overexpressed HCC4006 cell group.
need to dissect its precise roles in different cancer types. The genetic and environmental cues are believed to be critical to determine the function of FXR in a defined context. Specific ways by which FXR exerts proliferation-promoting functions in NSCLC were subsequently explored. Cell cycle arrest and apoptosis are considered two primary approaches underlying proliferation inhibition in cancer cells. We found that either pharmacological inhibition or knockdown of FXR delayed the NSCLC cell cycle G1/S transition. Interestingly, no detectable change in apoptosis was noted. Since the FXR antagonist guggulsterone was reported to induce cell apoptosis in esophageal cancer, pancreatic cancer, and head and neck cancer, among others, such discordance might be ascribed to the specific intrinsic characteristics across different tumor types 14, 24, 25 . Further experiments have been performed to assess the involvement of cell cycle regulators in the FXR-driven G1/S transition 18 . Cyclin D1, encoded by CCND1, is a well-documented regulator of the G1/S transition through activating CDK4/6 kinase and subsequently phosphorylating Rb 20 , that was dramatically reduced at both the protein and mRNA levels in the FXR-knockdown NSCLC cells, while it was increased in ectopic FXR-overexpressing cells. Our results support a reasonable mechanism that FXR facilitates NSCLC cell cycle G1/S transition via upregulation of cyclin D1 transcription. In accordance with our findings, cyclin D1 expression was concomitantly lower in hepatocyte-specific FXR knockout mice than in wild-type mice after partial hepatectomy in a previously published study 26 . However, we found that knockdown of SHP, a well-known FXR target gene mediating several major functions of FXR 8, 9 , neither affected NSCLC cell proliferation nor caused changes in cyclin D1 or p-Rb expression, indicating, at least in this context, that FXR-induced cell proliferation is SHP independent.
As a transcription factor, FXR regulates target gene expression by binding, either as a monomer or as a heterodimer with RXRα, to an FXRE sequence 27 . Many FXR target genes have been characterized, and they are involved in a variety of pathophysiological processes, including tumorigenesis [28] [29] [30] [31] . In this study, we demonstrated for the first time that FXR is recruited to the CCND1 promoter in NSCLC cells and activates its transcription. Furthermore, overexpression of cyclin D1 in FXR-suppressed NSCLC cells restored the cell cycle progression and in vitro proliferation, suggesting that FXR promotes NSCLC cell growth via the upregulation of cyclin D1 expression. Notably, we observed a positive correlation between the expression of FXR and cyclin D1 in NSCLC samples, and the shortest OS was observed in patients with both high FXR and high cyclin D1 expression, indicating a potential mechanistic link. In agreement with our findings, CCND1 is a well-recognized oncogene, as well as a poor prognostic indicator, that is overexpressed in many cancers, including NSCLC 22, 23 . Here, we provide a new biomarker, FXR, which, in combination with cyclin D1, more effectively sub-stratifies NSCLC patients. Moreover, recent research has shown that the therapeutic outcomes of targeted drugs are largely determined by the response of downstream effectors to the corresponding treatments [32] [33] [34] . This study supports the development of FXR-targeted therapies for NSCLC and enables the downstream effector cyclin D1 to act as a candidate probe for response or resistance to FXR-based treatments. Altogether, we found that FXR acts as a novel proto-oncogene in NSCLC via the target gene CCND1, driving cell cycle progression and tumor growth. The current study extends our understanding of the function for FXR in NSCLC tumorigenesis, providing a promising prognostic biomarker and therapeutic approach.
Materials and Methods
Patients and tissue microarray. Primary NSCLC and corresponding pericarcinous lung tissues were consecutively collected from the Department of Pathology in Ren Ji Hospital (Shanghai, China) between 2008 and 2010. Tissue microarrays (TMAs) were constructed as previously described 35 . For each sample, two cores with a 1.6-mm diameter were obtained from the original paraffin block. Clinicopathological information was retrospectively reviewed. The histology was determined according to the criteria of the World Health Organization, and pathological stages were classified according to the seventh edition of the lung cancer staging system 36 . Survival data were recorded on the basis of follow-up clinic visits or telephone calls. Patients who had incomplete clinical or follow-up data or who had received neoadjuvant chemotherapy or radiotherapy were excluded. In total, 160 patients were included. This study was approved by the Ethics Committee of Ren Ji Hospital, and informed consent was obtained from all participants. All methods were performed in accordance with the approved guidelines of School of Medical graduate Shanghai Jiao Tong University.
Immunohistochemical (IHC) analysis. IHC staining for FXR and cyclin D1 expression in TMAs was performed as described 4 . Anti-bile acid receptor (NR1H4) antibody (Abcam, Cambridge, MA) and anti-cyclin D1 antibody (Cell Signaling Technology, Beverly, MA) were applied at 1:100 and 1:50, respectively. Concentration-matched nonspecific rabbit IgG was used as a isotype control. Two trained pathologists viewed the IHC staining results and reached a final consensus. The scoring for the staining intensity was as follows: negative (0), weak (1), moderate (2) and intense (3) . The scoring for the percentage of positive cells was as follows: 0% (0), 1-25% (1), 26-50% (2), 51-75% (3) and 76-100% (4). The final FXR or cyclin D1 IHC score was obtained by multiplying the intensity and percentage scores, which were defined as low (including scores of 0-4) or high (6-12) expression.
Cell culture and cell proliferation assays. Human NSCLC cell lines (H1650, H460, HCC4006, H1975 and H1299), and a hepatoma cell line (HepG2) were purchased from the American Type Culture Collection (ATCC). All cells were cultured in RPMI-1640 or DMEM-F12 (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% FBS. The in vitro cell proliferation was assessed by sulforhodamine B (SRB) assay as previously described 37 . The absorbance was measured at 560 nm in a microplate reader.
Western blot. Western blot analysis was performed according to previously described procedures 16 . We used primary antibodies, including anti-bile acid receoptor (NR1H4) antibody, anti-SHP antibody (Santa Cruz, CA), anti-phospho-Rb antibody, anti-cyclin D1 antibody, anti-cyclin E1 antibody, anti-CDK2 antibody, anti-CDK4 Quantitative real-time PCR (RT-PCR) analysis. Quantitative RT-PCR was performed as previously described 16 . Primers were designed as follows: FXR forward, 5′-GATTGCTTTGCTGAAAGGGTC-3′; reverse, 5′-CAGAATGCCCAGACGGAAG-3′; SHP forward, 5′-AGGCCTCCAAGCCGCCTCCCACATTGGGC-3′; reverse, 5′-GCAGGCTGGTCGGAAACTTGAGGGT-3′; cyclin D1 forward, 5′-CGTGGGCTCTAAGATGAAGG-3′; reverse, 5′-TGCGGATGATCTGTTTGTTC-3′; β-actin forward, 5′-TTGCTGATCCACATCTGCT-3′; reverse, 5′-GACAGGATGCAGAAGGAGAT-3′.
Transfection. Cells were transfected with siRNA by using Lipofectamine RNAiMAX reagent (Invitrogen Corporation) according to the manufacturer's instructions. The target sequences of double-stranded nucleotides used in siRNA transfection were 5′-GGACCATGAAGACCAGATT-3′(FXRsiRNA-1) and 5′-GTAGCAGAGATGCCTGTAA-3′(FXRsiRNA-2) for FXR knockdown, 5′-GGAATATGCCTGCCTGAAA-3′(SHPsiRNA-1) and 5′-TCGCCCTATCATTGGAGAT-3′(SHPsiRNA-2) for SHP knockdown, and 5′-TTCTCCGAACGTGTCACGT-3′ as a negative control (NC) (RiboBio, Guangzhou, China). To perform rescue experiments, cells were transfected with pcDNA3.1(+)-cyclin D1-3Flag plasmids, constructed with OBiO Biotechnology (Shanghai, China), by using Lipofectamine 2000 (Invitrogen Corporation) according to the manufacturer's protocol. Empty pcDNA3.1(+)-3Flag plasmid was used as control.
Construction of lentiviral vectors and cell infection. Lentiviral vectors were constructed with OBiO
Biotechnology (Shanghai, China), using either pCMV-NR1H4-PGK-PuroR plasmids, which carry the full-length NR1H4 coding sequence (GenBank accession NM_005123.3), or pCMV-G&PR-U6-shRNA plasmids, which generate shRNA targeting FXR or NCshRNA as described above. The detailed methodology for cell infection is provided in the Supplementary Information.
Confocal immuofluorescence. After treatment, cells were grown on cover-slips with 1% gelatin for 24 h.
Confocal immuofluorescence was performed as previously described 16 . Anti-human Ki-67 antibody (Spring Bioscience, Fremont, CA) was applied at 1:100.
Tumorigenicity assays in nude mice. The Luciferase reporter assay. Luciferase reporter plasmids carrying either wild-type or FXRE-deleted CCND1 promoter sequence were generated by OBiO Biotechnology (Shanghai, China). The detailed methodology is provided in the Supplementary Information.
Chromatin immunoprecipitation (ChIP) assay. The ChIP assay was conducted using a SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to the manufacturer's instructions. The detailed methodology is provided in the Supplementary Information. Primers used in quantitative RT-PCR were as follows: cyclin D1 promoter, forward 5′-TAGGTGCTCCCTGCTGGGGC-3′; reverse 5′-ACCTTTCAGGGTGAATTCCTCCC-3′.
